Tendera-OB by is a Other medication manufactured, distributed, or labeled by BonGeo Pharmaceuticals, Inc.. Drug facts, warnings, and ingredients follow.
Supplement Facts | ||
---|---|---|
Serving Size: 1 Softgel | Servings Per Container: 90 | |
Amount Per Serving | % Daily Value in Pregnancy | |
|
||
Vitamin C (as Ascorbic Acid) | 40 mg | 67% |
Vitamin D (as Cholecalciferol) | 1000 IU | 250% |
Vitamin E (as d-Alpha- Tocopheryl Acetate) | 10 IU | 33% |
Vitamin B1 (as Thiamine Mononitrate) | 1.5 mg | 88% |
Vitamin B2 (as Riboflavin) | 2 mg | 100% |
Vitamin B3 (as Niacin) | 12 mg | 60% |
Vitamin B6 (as Pyridoxine HCl) | 3 mg | 120% |
Folate (as 400 mcg Quatrefolic R ((6S-5-meth-yltetrahydrofolic acid, glucosamine salt, molar equivalent to 216 mcg of folic acid)) and 784 mcg of folic acid) | 1 mg | 125% |
Vitamin B12 (as Cyanocobalamin 1%) | 15 mcg | 188% |
Iron (as Iron Carbonyl Powder) | 27 mg | 150% |
Iodine (as Potassium Iodide) | 150 mcg | 100% |
Magnesium (as Magnesium Oxide) | 10 mg | 3% |
Zinc (as Zinc Gluconate) | 5 mg | 33% |
Copper (as Copper Oxide) | 1 mg | 50% |
Docosahexaenoic Acid (DHA, Omega-3 Fish Oil) | 205 mg | * |
OTHER INGREDIENTS: Gelatin capsule (bovine gelatin, glycerin, purified water, Annatto and Caramel), yellow beeswax, sunflower, lecithin. Contains: Fish.
Tendera-OB™ Softgel capsules are dye free, lactose, gluten and sugar free. They do not contain any artificial flavors or sweeteners.
Tendera-OB™ is an orally administered multivitamin/multimineral fatty acid dietary supplement indicated to improve the nutritional status of women during pregnancy and in the postnatal period for both breastfeeding and non-breastfeeding mothers. Tendera-OB™ may also be beneficial in improving the nutritional status of women prior to conception.
Caution is recommended in patients taking anticonvulsant medications as folate may interfere with anticonvulsant medication, and may lower seizure threshold. Decreased patient response to methotrexate may occur due to supplementation of folic acid. Furthermore, anticonvulsant medications may interfere with folate metabolism.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.
Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR). Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding. Supplemental intake of omega 3 fatty acids such as DHA above 2 grams per day is not recommended. In individuals with hypercalcemia or other conditions that may lead to hypercalcemia such as hyperparathyroidism and those that form calcium- containing kidney stones, Vitamin D supplementation should be used with caution. Elevated levels of calcium in blood and soft tissues may result from high doses of Vitamin D.
Use caution supplementing iodine in patients with overactive thyroid.
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact BonGeo Pharmaceuticals, Inc. at 1-844-640-7607.
Tendera-OB™ is available as oval, dark red softgel capsules with an imprint "190". They are available in child-resistant bottles containing 90 softgels (52796-190-90). Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.]
Avoid excessive heat, light and moisture.
TENDERA-OB
ascorbic acid, cholecalciferol, .alpha.-tocopherol, thiamine mononitrate, riboflavin, niacin, pyridoxine hydrochloride, levomefolate glucosamine, cyanocobalamin, iron pentacarbonyl, potassium iodide, magnesium oxide, zinc gluconate, cupric oxide, and doconexent capsule |
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Supplement Facts | ||
Serving Size : | Serving per Container : | |
Amount Per Serving | % Daily Value | |
---|---|---|
color | ||
scoring | 1 | |
shape | ||
size (solid drugs) | 15 mm | |
imprint |
Labeler - BonGeo Pharmaceuticals, Inc. (964822022) |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TENDERA-OB 88251976 not registered Live/Pending |
BonGeo Pharmaceuticals Inc. 2019-01-07 |